Stephan Grupp, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, discusses the importance of having a common language for clinical research investigating chimeric antigen receptor T-cell (CAR-T) therapy in order to enable trial results to be compared. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.